HRMY - Harmony Biosciences Holdings, Inc.

31.16
0.110   0.353%

Share volume: 509,735
Last Updated: 04-28-2026
Pharmaceutical Products/Pharmaceutical Preparations: -0.12%

PREVIOUS CLOSE
CHG
CHG%
$31.05
0.11
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
66%
Profitability 87%
Dept financing 27%
Liquidity 75%
Performance 53%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
1.17%
1 Month
15.84%
3 Months
-15.46%
6 Months
6.28%
1 Year
5.84%
2 Year
6.53%
Key data
Stock price
$31.16
P/E Ratio 
13.56
DAY RANGE
$30.62 - $31.46
EPS 
$2.94
52 WEEK RANGE
$25.52 - $40.87
52 WEEK CHANGE
$5.73
MARKET CAP 
2.155 B
YIELD 
N/A
SHARES OUTSTANDING 
57.841 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
04-29-2025
BETA 
1.35
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,390,426
AVERAGE 30 VOLUME 
$880,064
Company detail
CEO: John C.s Jacobs
Region: US
Website: harmonybiosciences.com
Employees: 200
IPO year: 2020
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Harmony Biosciences Holdings, Inc. develops and commercializes therapies for patients with rare neurological disorders in the United States. WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.

Recent news